Decitabine for relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

Abstract

Relapse after allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains a main question on treatment failure. Current strategies for management that usually include salvage chemotherapy, donor lymphocytic infusion and second transplantation. Our study assessed the efficacy of decitabine (DAC) for treating patients with acute lymphoblastic leukemia (ALL) who relapsed after allogeneic hematopoietic stem cell transplantation (allo-HSCT). We retrospectively analyzed the outcomes of 12 patients with relapsed ALL after allo-HSCT who received DAC therapy. Nine patients received DAC combined with chemotherapy and donor stem cell infusion, and 3 patients received single- agent DAC. Ten of the 12 patients achieved complete remission (CR), 1 achieved a partial remission (PR), and 1 had no response (NR) after treatment at the latest follow-up (LFU), the median survival was 11.2 months (range, 3.8–34, 7 months). The 1- and 2-year overall survival (OS) rates were 50% (6/12) and 25% (3/12), respectively. Five patients were still alive; 4 had maintained CR and 1 was alive with disease. Patients with Philadelphia chromosome-positive ALL had higher survival rate than patients with Philadelphia chromosome-negative ALL (57.1% vs. 20%). No aggravated flares of graft-versus-host disease (GVHD) were observed during DAC treatment. Therefore, DAC may be a promising therapeutic agent for ALL recurrence after allo-HSCT.

Keywords

decitabine / acute lymphoblastic leukemia (ALL) / allogeneic hematopoietic stem cell transplantation (allo-HSCT) / relapse

References

[1] GoldstoneAH, RichardsSM, LazarusHM, et al. . In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood, 2008, 111(4): 1827-1833 PMID: 18048644

[2] GokbugetN, StanzeD, BeckJ, et al. . Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood, 2012, 120(10): 2032-2041 PMID: 22493293

[3] AndreolaG, LabopinM, BeelenD, et al. . Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years. Bone Marrow Transplant, 2015, 50(12): 1508-1512 PMID: 26389832

[4] JabbourE, IssaJP, Garcia-ManeroG, et al. . Evolution of decitabine development: accomplishments, ongoing investigations, and future strategies. Cancer, 2008, 112(11): 2341-2351 PMID: 18398832 PMCID: 4784235

[5] DerissenEJ, BeijnenJH, SchellensJH. Concise drug review: azacitidine and decitabine. Oncologist, 2013, 18(5): 619-624 PMID: 23671007 PMCID: 3662854

[6] SchubelerD. Function and information content of DNA methylation. Nature, 2015, 517(7534): 321-326 PMID: 25592537

[7] KimDY, LeeJH, ParkYH, et al. . Feasibility of hypomethylating agents followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome. Bone Marrow Transplant, 2012, 47(3): 374-379 PMID: 21478916

[8] de LimaM, GiraltS, ThallPF, et al. . Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study. Cancer, 2010, 116(23): 5420-5431 PMID: 20672358 PMCID: 5669059

[9] ChoiJ, RitcheyJ, PriorJL, et al. . In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood, 2010, 116(1): 129-139 PMID: 20424188 PMCID: 2904576

[10] TessoulinB, DelaunayJ, ChevallierP, et al. . Azacitidine salvage therapy for relapse of myeloid malignancies following allogeneic hematopoietic SCT. Bone Marrow Transplant, 2014, 49(4): 567-571 PMID: 24488048

[11] NieDM, WuQL, ZhuXX, et al. . Angiogenic factors are associated with development of acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. J Huazhong Univ Sci Technolog Med Sci, 2015, 35(5): 694-699 PMID: 26489624

[12] ZhongZD, LiL, WuYH, et al. . Analysis of seizure risk factors after allogeneic hematopoietic stem cell transplantation: a 8-case report and literature review. J Huazhong Univ Sci Technolog Med Sci, 2013, 33(5): 656-660 PMID: 24142716

[13] CairoMS, JordanCT, MaleyCC, et al. . NCI first International Workshop on the biology, prevention, and treatment of relapse after allogeneic hematopoietic stem cell transplantation: report from the committee on the biological considerations of hematological relapse following allogeneic stem cell transplantation unrelated to graft-versus-tumor effects: state of the science. Biol Blood Marrow Transplant, 2010, 16(6): 709-728 PMID: 20227509 PMCID: 3711411

[14] JagasiaMH, GreinixHT, AroraM, et al. . National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant, 2015, 21(3): 389-401.e381

[15] PoonLM, HamdiA, SalibaR, et al. . Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2013, 19(7): 1059-1064 PMID: 23644077

[16] SpyridonidisA, LabopinM, SchmidC, et al. . Outcomes and prognostic factors of adults with acute lymphoblastic leukemia who relapse after allogeneic hematopoietic cell transplantation. An analysis on behalf of the Acute Leukemia Working Party of EBMT. Leukemia, 2012, 26(6): 1211-1217

[17] JabbourE, GiraltS, KantarjianH, et al. . Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer, 2009, 115(9): 1899-1905 PMID: 19235255 PMCID: 4086213

[18] RavandiF, KantarjianH, CohenA, et al. . Decitabine with allogeneic peripheral blood stem cell transplantation in the therapy of leukemia relapse following a prior transplant: results of a phase I study. Bone Marrow Transplant, 2001, 27(12): 1221-1225 PMID: 11548839

[19] LiesveldJL, O'DwyerK, WalkerA, et al. . A phase I study of decitabine and rapamycin in relapsed/refractory AML. Leuk Res, 2013, 37(12): 1622-1627 PMID: 24138944

[20] LubbertM, RuterBH, ClausR, et al. . A multicenter phase II trial of decitabine as first-line treatment for older patients with acute myeloid leukemia judged unfit for induction chemotherapy. Haematologica, 2012, 97(3): 393-401 PMID: 22058219 PMCID: 3291594

[21] Van der MeulenJ, Van RoyN, Van VlierbergheP, et al. . The epigenetic landscape of T-cell acute lymphoblastic leukemia. Int J Biochem Cell Biol, 2014, 53: 547-557 PMID: 24786297

[22] QianJ, WangYL, LinJ, et al. . Aberrant methylation of the death-associated protein kinase 1 (DAPK1) CpG island in chronic myeloid leukemia. Eur J Haematol, 2009, 82(2): 119-123 PMID: 19018866

[23] PehlivanM, SercanZ, SercanHO. sFRP1 promoter methylation is associated with persistent Philadelphia chromosome in chronic myeloid leukemia. Leuk Res, 2009, 33(8): 1062-1067 PMID: 19118898

[24] GangulyS, AminM, DivineC, et al. . Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT). Ann Hematol, 2013, 92(4): 549-550 PMID: 23111661

[25] LuBY, ThanawalaSU, ZochowskiKC, et al. . Decitabine enhances chemosensitivity of early T-cell precursor-acute lymphoblastic leukemia cell lines and patient-derived samples. Leuk Lymphoma, 2016, 57(8): 1938-1941 PMID: 26726842

[26] GiraltS, DavisM, O'BrienS, et al. . Studies of decitabine with allogeneic progenitor cell transplantation. Leukemia, 1997, 11(1): S32-34 PMID: 9130690

[27] RembergerM, TorlenJ, RingdenO, et al. . Effect of total nucleated and CD34(+) cell dose on outcome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant, 2015, 21(5): 889-893 PMID: 25662230

[28] RambaldiA, VieroP, BassanR, et al. . G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation of resistant or relapsing acute leukemias. Leukemia, 1996, 10(5): 860-865 PMID: 8656684

[29] HambachL, LingKW, PoolJ, et al. . Hypomethylating drugs convert HA-1-negative solid tumors into targets for stem cell-based immunotherapy. Blood, 2009, 113(12): 2715-2722 PMID: 19096014

[30] EngelN, RankA. Epigenomics in hematopoietic transplantation: novel treatment strategies. Epigenomics, 2011, 3(5): 611-623 PMID: 22126249